



**FEBRUARY 27 & 28**



MDAnderson  
~~Cancer~~ Center  
Madrid · España



MDAnderson  
~~Cancer~~ Center  
Fundación · España

# SOHO **SPAIN** 2025

Rafael del Pino auditorium C. de Rafael Calvo 39A 28010  
Madrid, Spain



# SOHO SPAIN 2025

## A Society of Hematologic Oncology Regional/Satellite Meeting

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO's mission is to expedite worldwide research and education through the exchange of scientific information.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies, and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 9,500 members from 110 countries have joined the society from around the globe. To become a SOHO member, go to [www.soho.click/join](http://www.soho.click/join) and access the resources available exclusively to members. SOHO membership is free-of-charge. If you have any questions, you can contact SOHO membership at [admin@soho.org](mailto:admin@soho.org).



February 27&28

## Honorary President

**Dr. Hagop Kantarjian**

**Dra. María Victoria Mateos**

## Spanish Scientific committee

- **Dra. Ana Sureda**
- **Dr. Carlos Fernández de Larrea**
- **Dr. Carlos Panizo**
- **Dr. Fernando Martín Moro**
- **Dr. Francesc Bosch**
- **Dra. María Díez Campelo**
- **Dr. Pau Montesinos**
- **Dr. Ramón García-Sanz**
- **Dr. Valentín García Gutiérrez**

## Directors


### **Dr. Guillermo García-Manero**

University of Texas MD Anderson Cancer Center, Houston, USA

### **Dr. Adolfo de la Fuente Burguera**

MD Anderson Cancer Center Madrid - Hospiten, Spain

## International Scientific committee

- **Dr. Alessandro Isidori**
  - **Dr. Claudio Cerchione**
  - **Dr. Elías Jabbour**
  - **Dr. Naval Daver**
- 

## • 9:30h - 9:40h Welcome

### **Phil Scheinberg**

Hospital A Beneficência Portuguesa *São Paulo, Brazil*

### **Guillermo García-Manero**

University of Texas MD Anderson Cancer Center, *Houston, USA*

### **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

## 1. Multiple Myeloma (MM): Controversies in treatment

Moderator: **Carlos Fernández de Larrea**

Hospital Clinic of Barcelona. *Barcelona, Spain*

Moderator: **Verónica González de la Calle**

University Hospital of Salamanca. *Salamanca, Spain*

## • 9:40h - 10:10h **First-line treatment: Bortezomib, lenalidomide, and anti-CD38 for all?**

**Aurore Perrot**

Toulouse University Hospital. *Toulouse, France*

## • 10:10h - 10:30h **How to treat at relapse? Antibody-based approaches**

**Niels van de Donk**

Amsterdam University Medical Center. *Amsterdam, Netherlands*

## • 10:30h - 10:50h **How to treat at relapse? CAR-T cell-based strategies**

**Luis Gerardo Rodríguez**

Clinical Hospital of Barcelona. *Barcelona, Spain*

## • 10:50h - 11:20h **Discussion:** All speakers and moderators

• **11:20h - 11:40h** **Breaking News**

Claudio Cerchione

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST. *Meldola, Italy*

• **11:40h - 11:55h** **COFFEE BREAK**

## 2. Chronic Myeloid Leukemia (CML)

Moderator: Valentín García Gutiérrez

Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: Alicia Senin

Hospital Del Mar. *Barcelona, Spain*

• **11:55h - 12:15h** **Prognostic implications of cancer-associated mutations in CML**

Gonzalo Carreño

12 de Octubre University Hospital. *Madrid, Spain*

• **12:15h - 12:35h** **First-line therapy updates in CML patients**

Valentín García Gutiérrez

Ramón y Cajal University Hospital. *Madrid, Spain*

• **12:35h - 12:55h** **Treatment discontinuation in CML: Who, how, and when?**

Santiago Osorio

Gregorio Marañón, University Hospital. *Madrid, Spain*

• **12:55h - 13:10h** **Discussion**



## 3. Myelodysplastic Syndromes (MDS)

Moderator: **María Díez Campelo**

University of Salamanca. *Salamanca, Spain*

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

• **13:10h - 13:30h Rethinking classification and prognosis in MDS**

**Rami Komrokji**

Moffitt Cancer Center. *Houston, USA*

• **13:30h - 13:50h How to avoid transfusion dependence in low-risk MDS**

**Valeria Santini**

University of Florence Medical School. *Florence, Italy*

• **13:50h - 14:10h Targeted therapy and new targets in high-risk MDS**

**Guillermo García-Manero**

University of Texas MD Anderson Cancer Center. *Houston, USA*

• **14:10h - 14:25h Discussion**

## IDEOGEN Symposium Program

• **14:25h - 15:10h Advances in the management of T lymphomas: from the disease to clinical solutions**

**Ana García Noblejas**

Princess Hospital. *Madrid, Spain*

**Alejandra Blum**

Campo Grande Hospital, Recoletas Group. *Valladolid, Spain*

**Beatriz Urrego**

General Hospital of Catalunya. *Barcelona, Spain*



- **15:10h - 15:55h LUNCH** Sponsored by GSK

## **4. Acute Myeloid Leukemia (AML) NOVEL TARGETED THERAPIES FOR AML**

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Pau Montesinos**

La Fe Polytechnic University Hospital. *Valencia, Spain*

- **15:55h - 16:15h Menin inhibitors for AML. What does the future look like?**

**Cristina Papayannidis**

IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*

- **16:15h - 16:35h Emerging triplets and doublets with FLT3 inhibitors**

**Juan Bergua**

San Pedro de Alcántara Hospital. *Cáceres, Spain*

- **16:35h - 16:55h Current developments of IDH inhibitors: beyond ivosidenib for unfit AML patients**

**Rebeca Rodríguez**

La Fe Health Research Institute IIS La Fe. *Valencia, Spain*

- **16:55h - 17:10h Discussion**

- **17:10h - 17:25h COFFEE BREAK**

## 5.Lymphoma 1

Moderator: **Juan Fernando García García**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Ramón García Sanz**

Gregorio Marañón General University Hospital. *Madrid, Spain*

Moderator: **Fernando Martín Moro**

Ramón y Cajal University Hospital. *Madrid, Spain*

• **17:25h - 17:45h Lymphoma Classification How to develop a Future Unified Taxonomy**

**Miguel Ángel Piris**

*Jiménez Díaz Foundation. Madrid, Spain*

• **17:45h - 18:05h Towards targeted treatments on the front line**

**Alejandro Martín García Sancho**

*University Hospital of Salamanca. Salamanca, Spain*

• **18:05h - 18:25h Diffuse Large B-cell lymphoma sequencing of therapies in the relapse setting**

**Miguel Canales**

*University Clinic of Navarra. Pamplona, Spain*

• **18:25h - 18:45h Multidisciplinary approach in cutaneous T cell lymphoma**

**Miriam López Parra**

*University Hospital of Salamanca. Salamanca, Spain*

• **18:45h - 19:00h Discussion**

February 27

**Pre-dinner sympo**

**Advancing individualization of treatment in Chronic Lymphocytic Leukemia (CLL)**

Moderator: **Javier de la Serna**

12 de Octubre University Hospital. *Madrid, Spain*

**• 19:00h - 20:00h Highlights CLL**

**Lucrecia Yañez Marqués de Valdecilla**

Marqués de Valdecilla University Hospital - IDIVAL University of Cantabria. *Cantabria, Spain.*

**Panel discussion:**

**Individualization of treatment beyond cytogenetics**

**José Antonio García Vela**

Puerta De Hierro University Hospital. *Madrid, Spain*

**Almudena Navarro**

University Hospital of Salamanca. *Salamanca, Spain*

**• 21:00h**

**DINNER Sponsored by SANOFI**

Restaurant: Fortuny Home Club

Address: C. de Fortuny, 34

## SERB Symposium Program

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Jaime Verdú Amorós**

Hospital University Valencia. *Valencia, Spain*

### • 8:00h - 8:05h **Welcome**

#### **Challenges in the management of patients treated with HDMTX**

**Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

### • 8:05h - 8:25h **Review of guidelines and protocols for the management of adult patients treated with HDMTX**

**Anna Torrent Catarineu**

Catalan Institute of Oncology | Clinical Hematology | Germans Trias i Pujol Hospital. *Barcelona, Spain*

### • 8:25h - 8:50h **Glucarpidase (Voraxaze®) in acute MTX toxicity. Early diagnosis of delayed methotrexate elimination. "A European consensus recommendation on the treatment of late elimination of methotrexate: supportive measures, leucovorin rescue and glucarpidase treatment."**

**Thais Murciano Carrillo**

Vall d'Hebron University Hospital. *Barcelona, Spain*

### • 8:50h - 9:00h **Questions and discussion**

• **9:00h - 9:10h** **1. Introduction to the Chronic Lymphocytic Leukemia (CLL)**

Moderator: **Francesc Bosch**

Vall d'Hebron Hospital. *Barcelona, Spain*

Moderator: **Juan Marquet Palomanes**

Ramón y Cajal University Hospital. *Madrid, Spain*

Moderator: **José Francisco Tomás**

La Moraleja University Hospital / Virgen del Mar University Hospital. *Madrid, Spain*

• **9:10h - 9:20h** **Continuous vs. time-limited treatment**

• **9:20h - 9:30h** **Continuous vs. time-limited treatment** - In favor of continuous strategies

**Javier Loscertales**

La Princesa University Hospital. *Madrid, Spain*

• **9:30h - 9:40h** **Continuous vs. time-limited treatment** - In favor of time-limited strategies (**Straming session**)

**Othman Al-Sawaf**

University Hospital Cologne. *Cologne, Germany*

• **9:40h - 9:50h** **Continuous vs. time-limited treatment** - Discussion

• **9:50h - 10:00h** **Continuous vs. time-limited treatment**

• **10:00h - 10:15h** **Sequencing treatment after front-line BTKi**

**Almudena Navarro**

University Hospital of Salamanca. *Salamanca, Spain*

• **10:15h - 10:30h Sequencing treatment after time-limited therapy**

Lucrecia Yáñez

Marqués de Valdecilla University Hospital - IDIVAL

University of Cantabria. *Cantabria, Spain*

• **10:30h - 10:45h Richter transformation**

Pau Abrisqueta

Vall d'Hebron Hospital. *Barcelona, Spain*

• **10:45h - 11:00h COFFEE BREAK**

## 2. Negative Philadelphia Myeloproliferative Neoplasms

Moderator: Valentín García Gutiérrez

Ramón y Cajal University Hospital *Madrid, Spain*

Moderator: Lucía Pérez Lamas

Puerta de Hierro University Hospital. *Madrid, Spain*

• **11:00h - 11:20h New developments in diagnosis and molecular monitoring of Philadelphia-negative myeloproliferative neoplasms**

Beatriz Bellosillo

Hospital del Mar. *Barcelona, Spain*

• **11:20h - 11:40h Interferon in Polycythemia Vera, how, when and to whom?**

Miguel Piris

Ramón y Cajal University Hospital. *Madrid, Spain*



• **11:40h - 12:00h** **Optimizing Treatment for Myelofibrosis: A Personalized Approach**

Francesca Palandri

IRCCS Azienda Ospedaliero-Universitaria di Bologna. *Bologna, Italy*

• **12:00h - 12:15h** **Discussion**

### 3.Lymphoma 2

Moderator: **Carlos Montalbán**

MD Anderson Cancer Center Madrid – Hospiten. *Madrid, Spain*

Moderator: **Ramón García Sanz**

Gregorio Marañón General University Hospital, *Madrid, Spain*

Moderator: **Sara Alonso Álvarez**

Hospital Universitario Central de Asturias. ISPA. IUOPA. *Oviedo, Spain*

• **12:15 - 12:35h** **Breaking News**

Luis Fayad

MD Anderson Cancer Center. *Houston, USA*

• **12:35h - 12:55h** **Advanced Hodgkin lymphoma: can we improve first-line treatment? (Straming session)**

Peter Borchmann

University Hospital of Cologne. *Cologne, Germany*

• **12:55h - 13:15h** **Choosing Between a BTK Inhibitor & Car T-Cell Therapy in RR MCL**

Ana Marín Niebla

Vall d'Hebron University Hospital. *Barcelona, Spain*

• **13:15h - 13:35h** **Discussion**



## DAIICHI SANKIO Symposium Program

### How molecular information guide treatment decisions

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Claudia Núñez-Torrón Stock**

Infanta Sofía University Hospital. *Madrid, Spain*

• **13:35h - 14:20h Genetic study in myeloblastic leukemia at diagnosis**

**Margarida Coucelo**

Pediatric Hospital of Coimbra. *Coimbra, Portugal*

### The evolving role of FLT3 inhibitors for AML

**Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten *Madrid, Spain*

• **14:20h - 15:30h LUNCH**

## 4. Transplant and Cell Therapy

Moderator: **Ana Alarcón Tomás**

Puerta de Hierro University Hospital. *Madrid, Spain*

Moderator: **Carlos Panizo**

Donostia University Hospital. *San Sebastián, Spain*

Moderator: **Ana Sureda**

Catalan Institute of Oncology (ICO). *Barcelona, Spain*

• **15:30h - 15:50h CART cells in acute myeloblastic leukemia**

**Nela Klein**

Hospital Clinic Barcelona. *Barcelona, Spain*

- **15:50h - 16:10h Post-CART relapses in patients with B lymphoma: Mechanisms of resistance and potential therapeutic strategies. (Streaming session)**

Roni Shouval

Memorial Sloan Kettering Cancer Center, *New York, USA*

- **16:10h - 16:30h Role of hematopoietic stem cell transplantation in lymphomas in 2025**

Leyre Bento

Son Espases Hospital. *Palma de Mallorca, Spain*

- **16:30h - 16:45h Discussion**

- **16:45h - 17:00h COFFEE BREAK**

## 5.Lymphoma 3

Moderator: **Carlos Montalbán**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Alejandro Bobes**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Carlos Panizo**

Donostia University Hospital. *San Sebastián, Spain*

- **17:00h - 17:20h Follicular Lymphoma management algorithm in 2025**

**Armando López Guillermo**

Hospital Clinic of Barcelona. *Barcelona, Spain*

- **17:20h - 17:40h POD24 it's not all the same**

**Ana Muntañola**

Hospital de la Santa Creu i Sant Pau. *Barcelona, Spain*

- **17:40h - 17:50h Discussion**

## • 17:50h - 18:10h **Breaking News in Acute Leukemia**

Moderator: **Luis Pedro Monteiro**

ULS São José. *Lisbon, Portugal*

Moderator: **Carlos Jiménez Chillón**

Gregorio Marañón University Hospital. *Madrid, Spain*

## **Myeloblastic Leukemia**

**Naval Daver**

MD Anderson Cancer Center. *Houston, US*

## **Lymphoblastic Leukemia**

**Elías Jabbour**

MD Anderson Cancer Center. *Houston, US*

## **6.Acute Myeloid Leukemia (AML) From clinical trials to real-life data in AML**

Moderator: **Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten. *Madrid, Spain*

Moderator: **Pau Montesinos**

La Fe Polytechnic University Hospital. *Valencia, Spain*

## • 18:10h - 18:30h **Real world practice with Venetoclax-based regimens for unfit AML**

**Stephane de Botton**

Institut Gustave Roussy. *Paris, France*

## • 18:30h - 18:50h **International experience with CPX-351 for high-risk fit AML**

**Teresa Bernal**

Central University Hospital of Asturias. *Oviedo, Spain*

## • 18:50h - 19:05h **Discussion**

February 28

• 19:05h - 19:10h **Farewell**

**Phil Scheinberg**

Hospital A Beneficência Portuguesa São Paulo, Brazil

**Guillermo García-Manero**

University of Texas MD Anderson Cancer Center. Houston, USA

**Adolfo de la Fuente**

MD Anderson Cancer Center Madrid - Hospiten, Spain.

Madrid, Spain

Organized by



MDAnderson  
Cancer Center  
Madrid · España

 Hospiten

MDAnderson  
Cancer Center  
Fundación · España



SPONSORS

PLATINUM

AstraZeneca 

**SERVIER**   
*moved by you*

GOLD

 **SERB**  
Pharmaceuticals

# SPONSORS

## SILVER

abbvie



Johnson  
& Johnson



Lilly

## BRONZE





# SPONSORS

## COLLABORATOR







Organized by



MDAnderson  
Cancer Center  
Madrid · España



MDAnderson  
Cancer Center  
Fundación · España

Accreditation

Credits requested from the Continuing Education Commission  
of Health Professions of the Community of Madrid

Venue

Rafael del Pino auditorium C. de Rafael Calvo 39A 28010  
Madrid, Spain

Technical Secretary



BioPress Ediciones Médicas SL  
C/Velázquez, 59, 5º Cl. 28001, MADRID  
ESPAÑA